Combined serum CXCL8, CXCL9 and CXCL13 tests for the prediction of microvascular invasion in hepatocellular carcinoma

Biomark Med. 2023 Mar;17(5):265-272. doi: 10.2217/bmm-2023-0064. Epub 2023 May 23.

Abstract

Aim: This work is to explore the predictive and diagnostic value of chemokine C-X-C motif ligand 8 (CXCL8), CXCL9 and CXCL13 combined detections for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients. Materials & methods: A total of 82 HCC patients with MVI were recruited as the MVI group and 154 patients with non MVI were recruited as the non MVI group. Results: In HCC patients with MVI, CXCL8, CXCL9, CXCL13 levels were significantly elevated. Child-Pugh scores and serum α-fetoprotein level had positive correlation with CXCL8, CXCL9 and CXCL13 levels. The serum levels of CXCL8, 9 and 13 were effective in predicting MVI in HCC patients. Conclusion: CXCL8, CXCL9 and CXCL13 levels in HCC patients are valuable parameters in the prediction of MVI.

Keywords: CXCL13; CXCL8; CXCL9; hepatocellular carcinoma; microvascular invasion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Chemokine CXCL13
  • Chemokine CXCL9
  • Humans
  • Liver Neoplasms* / pathology
  • Microvessels / pathology
  • Neoplasm Invasiveness
  • Retrospective Studies

Substances

  • Chemokine CXCL13
  • CXCL9 protein, human
  • Chemokine CXCL9
  • CXCL13 protein, human